FDA Grants Accelerated Approval to Bizengri for NSCLC and Pancreatic Adenocarcinoma

The FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for adults with the following:
• advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy, or
• advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy.

This is the first FDA approval of a